News
Needleless Corporation Partners with KFSYSCC, Min Aik Technology, and NYCU to Develop an Intelligent Drug Compounding System
Needleless Corporation Partners with KFSYSCC, Min Aik Technology, and NYCU to Develop an Intelligent Drug Compounding System — Setting a New Benchmark for Patient Safety in Cancer Care
Precision and safety have always been the ultimate goals and fundamental standards of clinical operations. Needleless Corporation, a pioneer in the development and manufacturing of Closed System Transfer Devices (CSTD), has long been dedicated to advancing medication safety in oncology treatment. In recent years, the company has expanded into the field of digital and smart healthcare, joining forces with KFSYSCC, Min Aik Technology, and National Yang Ming Chiao Tung University (NYCU) to co-develop the next-generation NM Intelligent Drug Compounding System.
This system integrates automation, artificial intelligence, and digital traceability technologies to enable direct linkage between physicians’ prescriptions and automated compounding processes. By significantly reducing manual operations and human error, the system enhances the precision and reliability of chemotherapy preparation, ensuring optimal therapeutic outcomes and patient safety.
Industry–Clinical–Academic Collaboration Realizes a Digitally Controlled, Error-Reduced Compounding Process
The NM Intelligent Drug Compounding System represents a deep collaboration between industry, medicine, and academia, combining clinical expertise, industrial engineering capabilities, and academic innovation in digital health.
Equipped with automated optical inspection (AOI) and real-time process monitoring, every compounding step is recorded and verified for accuracy. All data are automatically linked to the hospital’s Electronic Medical Record (EMR) system, forming a complete traceability chain from prescription to drug batch number, compounding records, delivery, and administration. Future integration of AI-assisted prescription verification will further advance the system toward comprehensive digital management.
Needleless: Driving the Transformation Toward Smart and Safe Healthcare
Mr. Chih-Wei Chien, General Manager of Needleless Corporation, stated,
“This collaboration with KFSYSCC, Min Aik Technology, and NYCU demonstrates our strength and innovation in CSTD technology. By combining the proven safety of our closed transfer system with NM’s intelligent control, pharmacists can now perform drug compounding more safely and efficiently than ever before.”
He further emphasized that this initiative is not merely a technical upgrade but a transformation in the culture of patient safety, reflecting Needleless Corporation’s ongoing commitment to integrating smart manufacturing and smart healthcare to protect both healthcare workers and patients.
Clinical Implementation Enhances Pharmacist Efficiency and Patient Safety
Dr. Shao-Ching Chiang, Deputy Director of the Pharmacy Department at KFSYSCC and Assistant Professor at NYCU, commented,
“Pharmacists have long been burdened with high-risk and repetitive compounding work. With the NM Intelligent Compounding System, physical and psychological workloads are greatly reduced, allowing pharmacists to focus on their true expertise—understanding patients, validating prescriptions, and monitoring treatment outcomes. This system truly empowers pharmacists to deliver safer, more patient-centered care.”
Mr. Hung-Jen Yang, COO of Min A Technology, added that automation is not intended to replace pharmacists but to empower them. Through human–machine collaboration, the system ensures a more precise, safer, and traceable drug compounding workflow—showcasing the tangible value of industry–medical–academic integration.
Establishing a New Standard for Taiwan’s Medical Innovation, Expanding Globally
KFSYSCC, Taiwan’s only dedicated cancer hospital, has maintained a five-year overall cancer survival rate of 75%, far exceeding the national average of 56%. The successful deployment of the NM Intelligent Drug Compounding System marks a new milestone in Taiwan’s advancement toward smart healthcare.
Needleless Corporation plans to further expand its partnerships with healthcare institutions and academic research centers, promoting international implementation of the NM system to benefit hospitals and cancer patients worldwide—delivering safer, more precise, and more efficient oncology drug management solutions.
About Needleless Corporation
Needleless Corporation specializes in the design and manufacture of Closed System Transfer Devices (CSTD), needle-free infusion interfaces, and smart medication management solutions. Its products are widely used in oncology chemotherapy, IV therapy, and hazardous drug preparation. Guided by the core principles of safety, precision, and innovation, Needleless is dedicated to advancing the integration of smart healthcare technologies and clinical applications, setting a new benchmark for patient safety.